BetterLife Pharma Inc.

OTCPK:BETR.F Stock Report

Market Cap: US$11.7m

BetterLife Pharma Management

Management criteria checks 3/4

BetterLife Pharma's CEO is Ahmad Doroudian, appointed in Jan 2020, has a tenure of 5.08 years. total yearly compensation is CA$439.81K, comprised of 68.2% salary and 31.8% bonuses, including company stock and options. directly owns 10.24% of the company’s shares, worth $1.19M. The average tenure of the management team and the board of directors is 3.1 years and 4.8 years respectively.

Key information

Ahmad Doroudian

Chief executive officer

CA$439.8k

Total compensation

CEO salary percentage68.2%
CEO tenure5.1yrs
CEO ownership10.2%
Management average tenure3.1yrs
Board average tenure4.8yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Ahmad Doroudian's remuneration changed compared to BetterLife Pharma's earnings?
DateTotal CompensationSalaryCompany Earnings
Oct 31 2024n/an/a

-CA$4m

Jul 31 2024n/an/a

-CA$5m

Apr 30 2024n/an/a

-CA$4m

Jan 31 2024CA$440kCA$300k

-CA$3m

Oct 31 2023n/an/a

-CA$2m

Jul 31 2023n/an/a

-CA$6m

Apr 30 2023n/an/a

-CA$6m

Jan 31 2023CA$300kCA$300k

-CA$9m

Oct 31 2022n/an/a

-CA$12m

Jul 31 2022n/an/a

-CA$10m

Apr 30 2022n/an/a

-CA$13m

Jan 31 2022CA$300kCA$300k

-CA$12m

Oct 31 2021n/an/a

-CA$36m

Jul 31 2021n/an/a

-CA$41m

Apr 30 2021n/an/a

-CA$39m

Jan 31 2021CA$160kCA$160k

-CA$36m

Oct 31 2020n/an/a

-CA$20m

Jul 31 2020n/an/a

-CA$15m

Apr 30 2020n/an/a

-CA$18m

Jan 31 2020CA$176kCA$176k

-CA$20m

Oct 31 2019n/an/a

-CA$11m

Jul 31 2019n/an/a

-CA$12m

Apr 30 2019n/an/a

-CA$9m

Jan 31 2019CA$459kCA$263k

-CA$9m

Compensation vs Market: Ahmad's total compensation ($USD307.35K) is below average for companies of similar size in the US market ($USD638.68K).

Compensation vs Earnings: Ahmad's compensation has increased whilst the company is unprofitable.

CEO

Ahmad Doroudian (64 yo)

5.1yrs

Tenure

CA$439,809

Compensation

Dr. Ahmad Doroudian, Ph D., is Founder of BetterLife Pharma Inc. and serves as its Chief Executive Officer and served as its Interim Chief Executive Officer. He serves as Director at BetterLife Pharma Inc....

Leadership Team

NamePositionTenureCompensationOwnership
Ahmad Doroudian
Founder5.1yrsCA$439.81k10.24%
$ 1.2m
Moira Ong
Chief Financial Officer14.2yrsCA$369.11k0.49%
$ 57.4k
Hooshmand Sheshbaradaran
Chief Operating Officer1.8yrsCA$550.79k1.07%
$ 124.8k
Stephen Sangha
Corporate Development Advisor1.7yrsno data15.85%
$ 1.8m
Scott Rudge
Head of CMCno datano datano data
Anthony Calandra
Head of Regulatory3.1yrsno datano data
Abdi Ghaffari
Head of Preclinical & Toxicology3.1yrsno datano data

3.1yrs

Average Tenure

64yo

Average Age

Experienced Management: BETR.F's management team is considered experienced (3.1 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Ahmad Doroudian
Founder5.1yrsCA$439.81k10.24%
$ 1.2m
Robert Metcalfe
Independent Director5.1yrsCA$63.82k0.023%
$ 2.7k
Wolfgang Renz
Independent Director10yrsCA$27.33k0.028%
$ 3.3k
Ralph Pullen
Independent Director4.8yrsCA$74.36k0.0023%
$ 270.5
Mark Swaim
Member of Advisory Boardno datano datano data
John McCorvy
Member of Scientific Advisory Board3.1yrsno datano data
Adam Halberstadt
Member of Scientific Advisory Board3.1yrsno datano data
Argel Aguilar-Valles
Member of Scientific Advisory Board3.1yrsno datano data

4.8yrs

Average Tenure

71.5yo

Average Age

Experienced Board: BETR.F's board of directors are considered experienced (4.8 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/10 17:53
End of Day Share Price 2025/02/10 00:00
Earnings2024/10/31
Annual Earnings2024/01/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

BetterLife Pharma Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.